Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | GLA | P06280 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10412478 | 0.84 | ALDH1A1 (0.56) | HPGDALDH1A1LMNAKDM4EGLA | |
| SCHEMBL8054422 | 0.83 | KDM4E (0.61) | HPGDALDH1A1LMNAKDM4EGLA | |
| SCHEMBL17211951 | 0.78 | ALDH1A1 (1.00) | HPGDALDH1A1LMNAKDM4EGLA | |
| SCHEMBL2010000 | 0.78 | MAOA (0.62) | HPGDALDH1A1LMNAKDM4EGLA | |
| SCHEMBL3605347 | 0.77 | KDM4E (1.00) | HPGDALDH1A1LMNAKDM4EGLA | |
| SCHEMBL9529549 | 0.77 | KDM4E (0.54) | HPGDALDH1A1LMNAKDM4EGLA | |
| SCHEMBL17724009 | 0.76 | MAOA (0.51) | HPGDALDH1A1LMNAKDM4EGLA | |
| SCHEMBL175987 | 0.76 | ALDH1A1 (0.59) | HPGDALDH1A1LMNAKDM4EGLA | |
| SCHEMBL9219100 | 0.76 | ADORA3 (0.50) | HPGDALDH1A1LMNAKDM4EGLA | |
| Hydrochloric Acid SCHEMBL11652791 | 0.76 | KDM4E (0.97) | HPGDALDH1A1LMNAKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884017-B2 | 2-heteroarylcarboxylic acid amides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-08-09 | — | — | US | disclosed |
| US-8076355-B2 | 2-heteroarylcarboxylic acid amides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
| EP-1461335-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003055878-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | HPGD 1585/4885ALDH1A1 1358/4885LMNA 2798/4885 |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | HPGD 2229/4885ALDH1A1 2223/4885LMNA 2429/4885 |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | HPGD 1585/4885ALDH1A1 1358/4885LMNA 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.